· Sanya will cancel the registration of two types of large and medium-sized vans

On March 2, the reporter learned from the traffic police department of Sanya that the department will cancel the registration of two types of large and medium-sized vans. These two types of vehicles are large and medium-sized vans that have not met the national retirement standards and have not been inspected regularly for two consecutive inspection cycles; after the service life specified by the national scrapping standards, a large inspection period has not been applied for periodic inspections. Medium-sized van.

The traffic police department will announce the large and medium-sized vans that have not been inspected in the city and have reached the above-mentioned cancellation registration conditions in the near future. Up to now, the deregistration will involve 527 vehicles that have not been inspected for two consecutive inspection cycles and 1,009 vehicles that have not been inspected during the inspection cycle.

It is understood that the Traffic Management Bureau of the Ministry of Public Security and the Provincial Traffic Police Corps issued documents last year, requesting further strict inspection of large and medium-sized vans. The traffic police department clarified that large and medium-sized passenger cars should focus on tire wear status, number of seats, equipped with seat belts, safety hammers, fire extinguishers and satellite positioning devices; large and medium-sized trucks focus on inspection of external dimensions, pasting body reflective signs, and installation side rear guards. Wait. For large and medium-sized vans, illegal modification and installation are carried out. Safety facilities are not installed according to the regulations. If the tread depth of the steering wheel is less than 3.2mm and the other tread depth is less than 1.6mm, it will not pass the inspection.

Anti-cancer Drug

China leading manufacturers and suppliers of Anticancer Drug , and we are specialized in Cabozantinib Intermediates, Alectinib Intermediates , Ceritinib Intermediates, Larotrectinib Intermediates, Ponatinib Intermediates , Ruxolitinib Intermediates,Anticancer Drug Development, etc.If you want to buy Anti-cancer Drugs,please contact us.


Cabozantinib, marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc.

Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib is approved by the U.S. FDA for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers.

Cabozantinib will be distributed in Europe by the French pharmaceutical company Ipsen after a collaboration was reached with Exelixis in March of 2016.


Alectinib is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors.


Ceritinib (INN, trade name Zykadia) is a drug for the treatment of a specific type of lung cancer. It is an anaplastic lymphoma kinase (ALK) inhibitor. It was developed by Novartis. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients that failed treatment with crizotinib. It is a more effective, but more toxic, alternative to traditional platinum-based chemotherapies. Ceritinib was found at physiological concentrations to inhibit ALK, insulin-like growth factor 1 receptor (IGF-1R), and ROS1.


Brigatinib (previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).


Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.


Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.



Anticancer Drug Classification,Anticancer Drug List, Cabozantinib Intermediates, Alectinib Intermediates, Ceritinib Intermediates, Larotrectinib Intermediates, Ponatinib Intermediates, Ruxolitinib Intermediates,,Anticancer Drug Development

 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com